1
|
Pfaller M, Huband M, Bien PA, Carvalhaes CG, Klauer A, Castanheira M. In vitro activity of manogepix and comparators against infrequently encountered yeast and mold isolates from the SENTRY Surveillance Program (2017-2022). Antimicrob Agents Chemother 2024; 68:e0113223. [PMID: 38205999 PMCID: PMC10848754 DOI: 10.1128/aac.01132-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2023] [Accepted: 11/21/2023] [Indexed: 01/12/2024] Open
Abstract
Manogepix is a potent new antifungal agent targeting the fungal Gwt1 enzyme. Manogepix has previously demonstrated potent in vitro activity against clinical isolates of both Candida (except Candida krusei) and Aspergillus species. This study determined the in vitro activity of manogepix and comparators against a large collection of infrequently encountered yeast and molds. Manogepix demonstrated potent in vitro activity against infrequently encountered yeasts exhibiting elevated MIC values to other drug classes, including Candida spp. (MIC50/90, 0.008/0.12 mg/L), Saprochaete clavata (Magnusiomyces clavatus) (MIC50/90, 0.03/0.06 mg/L), Magnusiomyces capitatus (MICrange, 0.016-0.06 mg/L), Rhodotorula minuta (MIC, 0.016 mg/L), and Rhodotorula mucilaginosa (MIC50/90, 0.03/0.12 mg/L). Similarly, manogepix was active against infrequently encountered mold isolates and strains exhibiting elevated MIC/MEC values to echinocandins, azoles, and amphotericin B, including Coprinopsis cinerea (MEC, 0.004 mg/L), Fusarium spp. (MEC50/90, 0.016/0.06 mg/L), Fusarium (Gibberella) fujikuroi species complex (MEC50/90, 0.016/0.03 mg/L), Lomentospora prolificans (MEC50/90, 0.03/0.06 mg/L), Microascus cirrosus (MEC, 0.008 mg/L), Paecilomyces spp. (MEC50/90, ≤0.008/0.016 mg/L), Pleurostomophora richardsiae (MEC, 0.06 mg/L), Sarocladium kiliense (MEC range, 0.016-0.12 mg/L), and Scedosporium spp. (MEC50/90, 0.03/0.06 mg/L). Manogepix demonstrated potent activity against a majority of the infrequently encountered yeast and mold isolates tested including strains with elevated MIC/MEC values to other drug classes. Additional clinical development of manogepix (fosmanogepix) in difficult-to-treat, resistant fungal infections is warranted.
Collapse
Affiliation(s)
- Michael Pfaller
- JMI Laboratories, North Liberty, lowa, USA
- University of Iowa, Iowa City, lowa, USA
| | | | - Paul A. Bien
- PAB Pharma Consulting LLC, San Diego, California, USA
| | | | | | | |
Collapse
|
2
|
Puttagunta S, Aronin S, Huband M, Flamm RK, Dunne M. 1363. Sulopenem Activity Against Enterobacteriaceae Isolates From Patients With Urinary Tract Infection or Intra-Abdominal Infection. Open Forum Infect Dis 2018. [PMCID: PMC6252987 DOI: 10.1093/ofid/ofy210.1194] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Background Sulopenem is a thiopenem antibacterial with oral and parenteral formulations being developed for the treatment of urinary tract infection (UTI) or complicated intra-abdominal infection (cIAI). The activity of sulopenem aligns with the most urgent drug-resistant antimicrobial threats defined by the Centers for Disease Control (CDC), including ESBL-producing strains of Escherichia coli and Klebsiella species. We evaluated the in vitro antibacterial activity of sulopenem against clinical Enterobacteriaceae isolates from patients in North America with UTI or cIAI collected during 2016–2017. Methods Sulopenem and other antimicrobial agents were tested for in vitro activity against 1,008 recent (2016–2017) consecutive Enterobacteriaceae isolates collected through the SENTRY Antimicrobial Surveillance Program from patients in North America with UTI (906 isolates) or cIAI (102 isolates). Reference broth microdilution susceptibility testing was conducted using frozen-form panels produced by JMI Laboratories according to CLSI (M07, 2018) guidelines using cation-adjusted Mueller–Hinton broth. Quality control (QC) and interpretation of results were performed in accordance with CLSI M100 (2018) guidelines. Results Table 1. Activity of sulopenem and comparator antimicrobial agents against 1,008 Enterobacteriaceae North American isolates The sulopenem MIC50/90 values for Enterobacteriaceae were 0.03/0.25 µg/mL. For Escherichia coli, Klebsiella species and Proteus mirabilis, the MIC50/90 results were 0.03/0.03 µg/mL, 0.03/0.06 µg/mL, and 0.12/0.25 µg/mL, respectively. Conclusion Sulopenem demonstrated potent in vitro activity against organisms commonly implicated in UTI and cIAI. These data support the further clinical development of sulopenem for Gram-negative infections. Disclosures S. Puttagunta, Iterum Therapeutics: Employee and Shareholder, Salary. S. Aronin, Iterum Therapeutics: Employee and Shareholder, Salary. M. Huband, JMI Labs: Research Contractor, Grant recipient. R. K. Flamm, Allergan: Research Contractor, Research support. M. Dunne, Iterum Therapeutics: Employee and Shareholder, Salary.
Collapse
|
3
|
Sader HS, Castanheira M, Huband M, Jones RN, Flamm RK. WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015. Antimicrob Agents Chemother 2017; 61:e00072-17. [PMID: 28242660 PMCID: PMC5404591 DOI: 10.1128/aac.00072-17] [Citation(s) in RCA: 58] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2017] [Accepted: 02/19/2017] [Indexed: 01/25/2023] Open
Abstract
WCK 5222 consists of cefepime combined with zidebactam, a bicyclo-acyl hydrazide β-lactam enhancer antibiotic with a dual action involving binding to Gram-negative bacterial PBP2 and β-lactamase inhibition. We evaluated the in vitro activity of cefepime-zidebactam against 7,876 contemporary (2015) clinical isolates of Enterobacteriaceae (n = 5,946), Pseudomonas aeruginosa (n = 1,291), and Acinetobacter spp. (n = 639) from the United States (n = 2,919), Europe (n = 3,004), the Asia-Pacific (n = 1,370), and Latin America (n = 583). The isolates were tested by a reference broth microdilution method for susceptibility against cefepime-zidebactam (1:1 and 2:1 ratios) and comparator agents. Cefepime-zidebactam was the most active compound tested against Enterobacteriaceae (MIC50/90, ≤0.03/0.12 μg/ml [1:1] and 0.06/0.25 μg/ml [2:1]; 99.9% of isolates were inhibited at ≤4 [1:1] and ≤8 μg/ml [2:1]). Cefepime-zidebactam was active against individual Enterobacteriaceae species (MIC50/90, ≤0.03 to 0.06/≤0.03 to 0.5 μg/ml [1:1]) and retained potent activity against carbapenem-resistant isolates (MIC50/90, 1/4 μg/ml; 99.3% of isolates were inhibited at ≤8 μg/ml [1:1]). Cefepime-zidebactam activity was consistent among geographic regions, and only one isolate showed MIC values of >8 μg/ml (1:1). Cefepime-zidebactam was also very active against P. aeruginosa with MIC50/90 values of 1/4 μg/ml, and 99.5% of isolates were inhibited at ≤8 μg/ml (1:1). The MIC values for cefepime-zidebactam at the 1:1 ratio were generally 2-fold lower than those for cefepime-zidebactam at the 2:1 ratio (MIC50/90, 2/8 μg/ml) and zidebactam alone (MIC50/90, 4/8 μg/ml). Against Acinetobacter spp., cefepime-zidebactam at 1:1 and 2:1 ratios (MIC50/90, 16/32 μg/ml for both) was 4-fold more active than cefepime or ceftazidime. Zidebactam exhibited potent in vitro antimicrobial activity against some organisms. These results support the clinical development of WCK 5222 for the treatment of Gram-negative bacterial infections, including those caused by multidrug-resistant isolates.
Collapse
|
4
|
Starr J, Brown MF, Aschenbrenner L, Caspers N, Che Y, Gerstenberger BS, Huband M, Knafels JD, Lemmon MM, Li C, McCurdy SP, McElroy E, Rauckhorst MR, Tomaras AP, Young JA, Zaniewski RP, Shanmugasundaram V, Han S. Siderophore Receptor-Mediated Uptake of Lactivicin Analogues in Gram-Negative Bacteria. J Med Chem 2014; 57:3845-55. [DOI: 10.1021/jm500219c] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Affiliation(s)
- Jeremy Starr
- Medicinal Chemistry, ⧧Computational Chemistry, §Antibacterials Research
Unit, and ¶Structural Biology, Pfizer Global Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Matthew F. Brown
- Medicinal Chemistry, ⧧Computational Chemistry, §Antibacterials Research
Unit, and ¶Structural Biology, Pfizer Global Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Lisa Aschenbrenner
- Medicinal Chemistry, ⧧Computational Chemistry, §Antibacterials Research
Unit, and ¶Structural Biology, Pfizer Global Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Nicole Caspers
- Medicinal Chemistry, ⧧Computational Chemistry, §Antibacterials Research
Unit, and ¶Structural Biology, Pfizer Global Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Ye Che
- Medicinal Chemistry, ⧧Computational Chemistry, §Antibacterials Research
Unit, and ¶Structural Biology, Pfizer Global Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Brian S. Gerstenberger
- Medicinal Chemistry, ⧧Computational Chemistry, §Antibacterials Research
Unit, and ¶Structural Biology, Pfizer Global Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Michael Huband
- Medicinal Chemistry, ⧧Computational Chemistry, §Antibacterials Research
Unit, and ¶Structural Biology, Pfizer Global Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - John D. Knafels
- Medicinal Chemistry, ⧧Computational Chemistry, §Antibacterials Research
Unit, and ¶Structural Biology, Pfizer Global Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - M. Megan Lemmon
- Medicinal Chemistry, ⧧Computational Chemistry, §Antibacterials Research
Unit, and ¶Structural Biology, Pfizer Global Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Chao Li
- Medicinal Chemistry, ⧧Computational Chemistry, §Antibacterials Research
Unit, and ¶Structural Biology, Pfizer Global Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Sandra P. McCurdy
- Medicinal Chemistry, ⧧Computational Chemistry, §Antibacterials Research
Unit, and ¶Structural Biology, Pfizer Global Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Eric McElroy
- Medicinal Chemistry, ⧧Computational Chemistry, §Antibacterials Research
Unit, and ¶Structural Biology, Pfizer Global Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Mark R. Rauckhorst
- Medicinal Chemistry, ⧧Computational Chemistry, §Antibacterials Research
Unit, and ¶Structural Biology, Pfizer Global Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Andrew P. Tomaras
- Medicinal Chemistry, ⧧Computational Chemistry, §Antibacterials Research
Unit, and ¶Structural Biology, Pfizer Global Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Jennifer A. Young
- Medicinal Chemistry, ⧧Computational Chemistry, §Antibacterials Research
Unit, and ¶Structural Biology, Pfizer Global Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Richard P. Zaniewski
- Medicinal Chemistry, ⧧Computational Chemistry, §Antibacterials Research
Unit, and ¶Structural Biology, Pfizer Global Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Veerabahu Shanmugasundaram
- Medicinal Chemistry, ⧧Computational Chemistry, §Antibacterials Research
Unit, and ¶Structural Biology, Pfizer Global Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Seungil Han
- Medicinal Chemistry, ⧧Computational Chemistry, §Antibacterials Research
Unit, and ¶Structural Biology, Pfizer Global Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| |
Collapse
|
5
|
Montgomery JI, Brown MF, Reilly U, Price LM, Abramite JA, Arcari J, Barham R, Che Y, Chen JM, Chung SW, Collantes EM, Desbonnet C, Doroski M, Doty J, Engtrakul JJ, Harris TM, Huband M, Knafels JD, Leach KL, Liu S, Marfat A, McAllister L, McElroy E, Menard CA, Mitton-Fry M, Mullins L, Noe MC, O'Donnell J, Oliver R, Penzien J, Plummer M, Shanmugasundaram V, Thoma C, Tomaras AP, Uccello DP, Vaz A, Wishka DG. Pyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious gram-negative infections. J Med Chem 2012; 55:1662-70. [PMID: 22257165 DOI: 10.1021/jm2014875] [Citation(s) in RCA: 79] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The synthesis and biological activity of a new series of LpxC inhibitors represented by pyridone methylsulfone hydroxamate 2a is presented. Members of this series have improved solubility and free fraction when compared to compounds in the previously described biphenyl methylsulfone hydroxamate series, and they maintain superior Gram-negative antibacterial activity to comparator agents.
Collapse
Affiliation(s)
- Justin I Montgomery
- Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Brown MF, Reilly U, Abramite JA, Arcari JT, Oliver R, Barham RA, Che Y, Chen JM, Collantes EM, Chung SW, Desbonnet C, Doty J, Doroski M, Engtrakul JJ, Harris TM, Huband M, Knafels JD, Leach KL, Liu S, Marfat A, Marra A, McElroy E, Melnick M, Menard CA, Montgomery JI, Mullins L, Noe MC, O'Donnell J, Penzien J, Plummer MS, Price LM, Shanmugasundaram V, Thoma C, Uccello DP, Warmus JS, Wishka DG. Potent inhibitors of LpxC for the treatment of Gram-negative infections. J Med Chem 2012; 55:914-23. [PMID: 22175825 DOI: 10.1021/jm2014748] [Citation(s) in RCA: 69] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
In this paper, we present the synthesis and SAR as well as selectivity, pharmacokinetic, and infection model data for representative analogues of a novel series of potent antibacterial LpxC inhibitors represented by hydroxamic acid.
Collapse
Affiliation(s)
- Matthew F Brown
- Worldwide Medicinal Chemistry, Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Abstract
Patients with head and neck defects may undergo reconstruction surgically, prosthetically, or with a combined approach. In some situations, prosthetic rehabilitation may be the preferred treatment option. Presurgical treatment planning and evaluation of the patient is paramount to successful reconstruction and rehabilitation. Patient education and assessment of the patient's expectations are essential in the acceptance of a proposed treatment plan. Communication and joint treatment planning early in the process between the surgeon and maxillofacial prosthodontist will optimize results.
Collapse
Affiliation(s)
- Michael Huband
- Maxillofacial Prosthetics, Section of Dentistry, Head and Neck Institute, Cleveland Clinic, 9500 Euclid Avenue/A71, Cleveland, Ohio 44195, USA.
| |
Collapse
|
8
|
Hutchings KM, Tran TP, Ellsworth EL, Watson BM, Sanchez JP, Showalter HD, Stier MA, Shapiro M, Themis Joannides E, Huband M, Nguyen DQ, Maiti S, Li T, Tailor J, Thomas G, Ha C, Singh R. Synthesis and antibacterial activity of the C-7 side chain of 3-aminoquinazolinediones. Bioorg Med Chem Lett 2008; 18:5087-90. [PMID: 18752951 DOI: 10.1016/j.bmcl.2008.07.117] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2008] [Revised: 07/29/2008] [Accepted: 07/31/2008] [Indexed: 10/21/2022]
Abstract
A novel series of bacterial topoisomerase (3-aminoquinazolinediones) inhibitors are described. The side-chain SAR against Gram-positive and Gram-negative organisms as well as DNA gyrase activity is reported.
Collapse
Affiliation(s)
- Kim M Hutchings
- Pfizer Global Research and Development, Michigan Laboratories, Ann Arbor Campus, 2800 Plymouth Road, Ann Arbor, MI 48105, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Murphy ST, Case HL, Ellsworth E, Hagen S, Huband M, Joannides T, Limberakis C, Marotti KR, Ottolini AM, Rauckhorst M, Starr J, Stier M, Taylor C, Zhu T, Blaser A, Denny WA, Lu GL, Smaill JB, Rivault F. The synthesis and biological evaluation of novel series of nitrile-containing fluoroquinolones as antibacterial agents. Bioorg Med Chem Lett 2007; 17:2150-5. [PMID: 17303420 DOI: 10.1016/j.bmcl.2007.01.090] [Citation(s) in RCA: 61] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2006] [Revised: 01/24/2007] [Accepted: 01/29/2007] [Indexed: 11/28/2022]
Abstract
Several novel series of nitrile-containing fluoroquinolones with weakly basic amines are reported which have reduced potential for hERG (human ether-a-go-go gene) channel inhibition as measured by the dofetilide assay. The new fluoroquinolones are potent against both Gram-positive and fastidious Gram-negative strains, including Methicillin resistant Staphylococcus aureus and fluoroquinolone-resistant Streptococcus pneumoniae. Several analogs also showed low potential for human genotoxicity as measured by the clonogenicity test. Compounds 22 and 37 (designated PF-00951966 and PF-02298732, respectively), which had good in vitro activity and in vitro safety profiles, also showed good pharmacokinetic properties in rats.
Collapse
Affiliation(s)
- Sean T Murphy
- Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, CA 92121, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Renslo AR, Gao H, Jaishankar P, Venkatachalam R, Gómez M, Blais J, Huband M, Vara Prasad JVN, Gordeev MF. Conformational constraint in oxazolidinone antibacterials. Part 2: Synthesis and structure–activity studies of oxa-, aza-, and thiabicyclo[3.1.0]hexylphenyl oxazolidinones. Bioorg Med Chem Lett 2006; 16:1126-9. [PMID: 16387498 DOI: 10.1016/j.bmcl.2005.11.093] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2005] [Revised: 11/23/2005] [Accepted: 11/28/2005] [Indexed: 11/25/2022]
Abstract
A new class of oxazolidinone antibacterials incorporating oxygen-, nitrogen-, or sulfur-containing heterobicyclic C-rings is described. The in vitro potency and in vivo efficacy of these conformationally constrained oxazolidinone analogs are discussed.
Collapse
Affiliation(s)
- Adam R Renslo
- Pfizer Global Research and Development, 34790 Ardentech Ct., Fremont, CA 94555, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Domagala JM, Alessi D, Cummings M, Gracheck S, Huang L, Huband M, Johnson G, Olson E, Shapiro M, Singh R, Song Y, Van Bogelen R, Vo D, Wold S. Bacterial two-component signalling as a therapeutic target in drug design. Inhibition of NRII by the diphenolic methanes (bisphenols). Adv Exp Med Biol 1999; 456:269-86. [PMID: 10549373 DOI: 10.1007/978-1-4615-4897-3_14] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Affiliation(s)
- J M Domagala
- Chemistry Department, Parke-Davis Pharmaceutical Research, Ann Arbor, Michigan 48105, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Hochstedler J, Huband M, Poillion C. Porcelain-fused-to-metal post and core: an esthetic alternative. J Dent Technol 1996; 13:26-9. [PMID: 9516278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Custom cast metal post and cores used to retain all-ceramic restorations are indicated in endodontically treated teeth when little clinical crown remains. The metal cores of these post and core restorations block light transmission and create a graying effect when used in support of all-ceramic restorations. This article describes a technique to minimize this effect using custom cast porcelain-fused-to-metal post and cores to achieve a more natural esthetic result.
Collapse
Affiliation(s)
- J Hochstedler
- Department of Prosthodontics, Louisiana State University School of Dentistry, New Orleans, USA
| | | | | |
Collapse
|
13
|
Huband M. The price of sex. Afr Rep 1991; 36:69-70. [PMID: 12348299] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/26/2023]
|